{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.984","upperLimit":"0.993","value":"0.990"},{"groupId":"OG001","lowerLimit":"0.976","upperLimit":"0.993","value":"0.987"}]}],"title":"0.5 Year"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.967","upperLimit":"0.981","value":"0.975"},{"groupId":"OG001","lowerLimit":"0.961","upperLimit":"0.985","value":"0.976"}]}],"title":"1 Year"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.950","upperLimit":"0.968","value":"0.960"},{"groupId":"OG001","lowerLimit":"0.939","upperLimit":"0.970","value":"0.957"}]}],"title":"1.5 Year"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.921","upperLimit":"0.944","value":"0.934"},{"groupId":"OG001","lowerLimit":"0.918","upperLimit":"0.955","value":"0.939"}]}],"title":"2 Years"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.889","upperLimit":"0.917","value":"0.904"},{"groupId":"OG001","lowerLimit":"0.870","upperLimit":"0.916","value":"0.896"}]}],"title":"3 Years"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.865","upperLimit":"0.896","value":"0.881"},{"groupId":"OG001","lowerLimit":"0.847","upperLimit":"0.897","value":"0.874"}]}],"title":"4 Years"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.851","upperLimit":"0.883","value":"0.868"},{"groupId":"OG001","lowerLimit":"0.835","upperLimit":"0.887","value":"0.863"}]}],"title":"5 Years"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.833","upperLimit":"0.867","value":"0.851"},{"groupId":"OG001","lowerLimit":"0.824","upperLimit":"0.878","value":"0.853"}]}],"title":"6 Years"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1865"},{"groupId":"OG001","value":"708"}],"units":"Participants"}],"description":"DFS is defined as the time from first dose of SC Herceptin to the first event of local, regional or distant recurrence, contralateral invasive breast cancer (including ipsilateral ductal carcinoma in situ) or death due to any cause.\n\nTime from the date of first dose to any DFS event was expressed in Kaplan-Meier survival probability estimates. Patients without an event will be censored at the last assessment date.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received SC Herceptin by an assisted administration as 600 mg every 3 weeks for a total of 18 doses/cycles. Each dose of SC Herceptin was taken from a single-use vial and injected by needle/syringe.","id":"OG000","title":"Cohort A: SC Herceptin by Needle/Syringe"},{"description":"Participants received SC Herceptin as 600 mg every 3 weeks for a total of 18 doses/cycles. Each dose of SC Herceptin was administered from a pre-filled SID. The first administration was performed by an HCP. Subsequent doses were self-administered by participants who were willing and judged competent by the HCP.","id":"OG001","title":"Cohort B: SC Herceptin by SID"}],"paramType":"NUMBER","populationDescription":"ITT Population who completed Safety Follow-up","reportingStatus":"POSTED","timeFrame":"From Baseline to time of event (up to approximately 8 years)","title":"Disease-Free Survival Rate","type":"SECONDARY","unitOfMeasure":"Kaplan-Meier survival probability"}